Skip to content

Abliva

Delivering mitochondrial health

  • English
    • English
    • Svenska
  • Abliva
    • This is Abliva
      • Delivering mitochondrial health
      • Orphan Drugs
    • Relevant publications
  • Mitochondrial Disease
    • Primary mitochondrial disease
      • MELAS-MIDD and KSS-CPEO
      • Leigh Syndrome
      • LHON
    • Patients
    • Expanded access policy
  • Research & Development
    • Portfolio
      • KL1333
      • NV354
      • Early programs
    • Clinical trials
      • The FALCON Study
  • Contact
    • Privacy policy

Press releases

  • All
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
All MARRegulatory
3 March, 2025
Regulatory

Delisting of the shares of Abliva: last day of trading 17 March 2025

In accordance with Nasdaq Stockholm AB’s decision, following an application from the Board of Directors of Abliva AB (publ), the shares of Abliva will be delisted from Nasdaq Stockholm. The [&he ...
Continue reading
26 February, 2025
Regulatory

Notice of Extraordinary General Meeting in Abliva AB (publ)

At the request of Pharming Technologies B.V. (“Pharming”), a wholly-owned subsidiary of Pharming Group N.V., which, following its public offer to the shareholders of Abliva AB (publ) (“Abliva”), holds ...
Continue reading
25 February, 2025
Regulatory

Abliva applies for delisting and will convene an extraordinary general meeting

The outcome of the extended acceptance period in the public offer from Pharming Technologies B.V. (“Pharming”), a wholly-owned subsidiary of Pharming Group N.V., regarding Abliva AB (publ) ...
Continue reading
21 February, 2025
Regulatory

Abliva AB Year-End Report January – December 2024

Positive Interim Analysis of the FALCON Study
Continue reading
15 December, 2024
Regulatory

Statement by the Board of Directors of Abliva regarding the public cash offer from Pharming

The Board of Directors unanimously recommends the shareholders to accept the offer.
Continue reading
29 November, 20249 December, 2024
Regulatory

Abliva AB Interim Report January – September 2024

- Positive Interim Analysis of the FALCON Study Paves the Way for KL1333 Development -
Continue reading
30 August, 20249 December, 2024
Regulatory

Amended number of shares and votes in Abliva AB (publ)

Abliva AB (Nasdaq Stockholm: ABLI) today announces that the number of shares and votes in the Company has increased by 262,500,000, as a result of the conversion of a convertible loan announced by the ...
Continue reading
22 August, 20249 December, 2024
Regulatory

Abliva AB Interim Report January – June 2024

FALCON Positioned for Success Following Analysis by Independent Committee ⎮ Strong Safety Profile Confirmed, and Both Primary Endpoints Passed Futility
Continue reading
19 July, 2024
Regulatory

Positive interim analysis in Abliva’s FALCON study triggers convertible loan conversion

Abliva AB (Nasdaq Stockholm: ABLI) a clinical-stage company developing medicines for the treatment of rare and severe primary mitochondrial disease, today announced that the convertible loan of SEK 42 ...
Continue reading
18 July, 2024
Regulatory

Abliva Announces Positive Interim Analysis of the FALCON Study for KL1333 in Primary Mitochondrial Disease

-Independent committee confirms FALCON study is powered for potential success with both alternative endpoints passing futility- -Committee confirms strong safety profile of KL1333- -Abliva to hos ...
Continue reading
31 May, 2024
Regulatory

Amended number of shares and votes in Abliva AB (publ)

Abliva AB (Nasdaq Stockholm: ABLI) today announces that the number of shares and votes in the Company has increased by 103,149,954, as a result of a preferential rights issue announced by the Board of ...
Continue reading
23 May, 2024
Regulatory

Resolutions from Annual General Meeting in Abliva AB (publ) on May 23, 2024

Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) today on May 23, 2024, held its Annual General Meeting (“AGM”). A summary of the resolution follows.
Continue reading

Posts navigation

Older posts
  1. Startpage

This is Abliva

  • Delivering mitochondrial health
  • Orphan Drugs
  • Relevant publications

Research & Development

  • Research & Development
  • KL1333
  • NV354
  • Early programs
  • The FALCON Study

Contact

Abliva AB (publ)
Medicon Village
223 81 Lund, Sweden

Phone
+46 (0)46-275 62 20

Generel questions
info@abliva.com

© Copyright 2020 – Abliva AB. All rights reserved. | We use cookies to improve our services | Cookie policy | Privacy policy

Cookies
We serve cookies. If you think that's ok, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings". Read our cookie policy
Settings Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy
  • Necessary
    These cookies are not optional. They are needed for the website to function.
  • Statistics
    In order for us to improve the website's functionality and structure, based on how the website is used.
  • Experience
    In order for our website to perform as well as possible during your visit. If you refuse these cookies, some functionality will disappear from the website.
  • Marketing
    By sharing your interests and behavior as you visit our site, you increase the chance of seeing personalized content and offers.
Save Accept all